Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients

Erin E. Talbert, Heather L. Lewis, Matthew R. Farren, Mitchell L. Ramsey, Jeffery M. Chakedis, Priyani Rajasekera, Ericka Haverick, Angela Sarna, Mark Bloomston, Timothy M. Pawlik, Teresa Zimmers, Gregory B. Lesinski, Phil A. Hart, Mary E. Dillhoff, Carl R. Schmidt, Denis C. Guttridge

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Cancer-associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of cancer patients but remains difficult to recognize and diagnose. While increases in circulating levels of a number of inflammatory cytokines have been associated with cancer cachexia, these associations were generally made in patients with advanced disease and thus may be associated with disease progression rather than directly with the cachexia syndrome. Thus, we sought to assess potential biomarkers of cancer-induced cachexia in patients with earlier stages of disease. Methods: A custom multiplex array was used to measure circulating levels of 25 soluble factors from 70 pancreatic cancer patients undergoing attempted tumour resections. A high-sensitivity multiplex was used for increased sensitivity for nine cytokines. Results: Resectable pancreatic cancer patients with cachexia had low levels of canonical pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-1β (IL-1β), interferon-γ (IFN-γ), and tumour necrosis factor (TNF). Even in our more sensitive analysis, these cytokines were not associated with cancer cachexia. Of the 25 circulating factors tested, only monocyte chemoattractant protein-1 (MCP-1) was increased in treatment-naïve cachectic patients compared with weight stable patients and identified as a potential biomarker for cancer cachexia. Although circulating levels of leptin and granulocyte-macrophage colony-stimulating factor (GM-CSF) were found to be decreased in the same cohort of treatment-naïve cachectic patients, these factors were closely associated with body mass index, limiting their utility as cancer cachexia biomarkers. Conclusions: Unlike in advanced disease, it is possible that cachexia in patients with resectable pancreatic cancer is not associated with high levels of classical markers of systemic inflammation. However, cachectic, treatment-naïve patients have higher levels of MCP-1, suggesting that MCP-1 may be useful as a biomarker of cancer cachexia.

Original languageEnglish (US)
Pages (from-to)358-368
Number of pages11
JournalJournal of Cachexia, Sarcopenia and Muscle
Volume9
Issue number2
DOIs
StatePublished - Apr 1 2018

Fingerprint

Cachexia
Chemokine CCL2
Pancreatic Neoplasms
Tumor Biomarkers
Cytokines
Therapeutics
Neoplasms
Granulocyte-Macrophage Colony-Stimulating Factor
Leptin
Interleukin-1
Interferons
Disease Progression
Interleukin-6
Body Mass Index
Tumor Necrosis Factor-alpha
Inflammation
Morbidity
Weights and Measures

Keywords

  • Biomarker
  • Wasting
  • Weight loss

ASJC Scopus subject areas

  • Biophysics
  • Applied Microbiology and Biotechnology
  • Orthopedics and Sports Medicine
  • Physiology (medical)

Cite this

Talbert, E. E., Lewis, H. L., Farren, M. R., Ramsey, M. L., Chakedis, J. M., Rajasekera, P., ... Guttridge, D. C. (2018). Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 9(2), 358-368. https://doi.org/10.1002/jcsm.12251

Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. / Talbert, Erin E.; Lewis, Heather L.; Farren, Matthew R.; Ramsey, Mitchell L.; Chakedis, Jeffery M.; Rajasekera, Priyani; Haverick, Ericka; Sarna, Angela; Bloomston, Mark; Pawlik, Timothy M.; Zimmers, Teresa; Lesinski, Gregory B.; Hart, Phil A.; Dillhoff, Mary E.; Schmidt, Carl R.; Guttridge, Denis C.

In: Journal of Cachexia, Sarcopenia and Muscle, Vol. 9, No. 2, 01.04.2018, p. 358-368.

Research output: Contribution to journalArticle

Talbert, EE, Lewis, HL, Farren, MR, Ramsey, ML, Chakedis, JM, Rajasekera, P, Haverick, E, Sarna, A, Bloomston, M, Pawlik, TM, Zimmers, T, Lesinski, GB, Hart, PA, Dillhoff, ME, Schmidt, CR & Guttridge, DC 2018, 'Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients', Journal of Cachexia, Sarcopenia and Muscle, vol. 9, no. 2, pp. 358-368. https://doi.org/10.1002/jcsm.12251
Talbert, Erin E. ; Lewis, Heather L. ; Farren, Matthew R. ; Ramsey, Mitchell L. ; Chakedis, Jeffery M. ; Rajasekera, Priyani ; Haverick, Ericka ; Sarna, Angela ; Bloomston, Mark ; Pawlik, Timothy M. ; Zimmers, Teresa ; Lesinski, Gregory B. ; Hart, Phil A. ; Dillhoff, Mary E. ; Schmidt, Carl R. ; Guttridge, Denis C. / Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. In: Journal of Cachexia, Sarcopenia and Muscle. 2018 ; Vol. 9, No. 2. pp. 358-368.
@article{9cf209d95a7a49628508695bfc36fc25,
title = "Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-na{\"i}ve pancreatic cancer patients",
abstract = "Background: Cancer-associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of cancer patients but remains difficult to recognize and diagnose. While increases in circulating levels of a number of inflammatory cytokines have been associated with cancer cachexia, these associations were generally made in patients with advanced disease and thus may be associated with disease progression rather than directly with the cachexia syndrome. Thus, we sought to assess potential biomarkers of cancer-induced cachexia in patients with earlier stages of disease. Methods: A custom multiplex array was used to measure circulating levels of 25 soluble factors from 70 pancreatic cancer patients undergoing attempted tumour resections. A high-sensitivity multiplex was used for increased sensitivity for nine cytokines. Results: Resectable pancreatic cancer patients with cachexia had low levels of canonical pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-1β (IL-1β), interferon-γ (IFN-γ), and tumour necrosis factor (TNF). Even in our more sensitive analysis, these cytokines were not associated with cancer cachexia. Of the 25 circulating factors tested, only monocyte chemoattractant protein-1 (MCP-1) was increased in treatment-na{\"i}ve cachectic patients compared with weight stable patients and identified as a potential biomarker for cancer cachexia. Although circulating levels of leptin and granulocyte-macrophage colony-stimulating factor (GM-CSF) were found to be decreased in the same cohort of treatment-na{\"i}ve cachectic patients, these factors were closely associated with body mass index, limiting their utility as cancer cachexia biomarkers. Conclusions: Unlike in advanced disease, it is possible that cachexia in patients with resectable pancreatic cancer is not associated with high levels of classical markers of systemic inflammation. However, cachectic, treatment-na{\"i}ve patients have higher levels of MCP-1, suggesting that MCP-1 may be useful as a biomarker of cancer cachexia.",
keywords = "Biomarker, Wasting, Weight loss",
author = "Talbert, {Erin E.} and Lewis, {Heather L.} and Farren, {Matthew R.} and Ramsey, {Mitchell L.} and Chakedis, {Jeffery M.} and Priyani Rajasekera and Ericka Haverick and Angela Sarna and Mark Bloomston and Pawlik, {Timothy M.} and Teresa Zimmers and Lesinski, {Gregory B.} and Hart, {Phil A.} and Dillhoff, {Mary E.} and Schmidt, {Carl R.} and Guttridge, {Denis C.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1002/jcsm.12251",
language = "English (US)",
volume = "9",
pages = "358--368",
journal = "Journal of Cachexia, Sarcopenia and Muscle",
issn = "2190-5991",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients

AU - Talbert, Erin E.

AU - Lewis, Heather L.

AU - Farren, Matthew R.

AU - Ramsey, Mitchell L.

AU - Chakedis, Jeffery M.

AU - Rajasekera, Priyani

AU - Haverick, Ericka

AU - Sarna, Angela

AU - Bloomston, Mark

AU - Pawlik, Timothy M.

AU - Zimmers, Teresa

AU - Lesinski, Gregory B.

AU - Hart, Phil A.

AU - Dillhoff, Mary E.

AU - Schmidt, Carl R.

AU - Guttridge, Denis C.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Cancer-associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of cancer patients but remains difficult to recognize and diagnose. While increases in circulating levels of a number of inflammatory cytokines have been associated with cancer cachexia, these associations were generally made in patients with advanced disease and thus may be associated with disease progression rather than directly with the cachexia syndrome. Thus, we sought to assess potential biomarkers of cancer-induced cachexia in patients with earlier stages of disease. Methods: A custom multiplex array was used to measure circulating levels of 25 soluble factors from 70 pancreatic cancer patients undergoing attempted tumour resections. A high-sensitivity multiplex was used for increased sensitivity for nine cytokines. Results: Resectable pancreatic cancer patients with cachexia had low levels of canonical pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-1β (IL-1β), interferon-γ (IFN-γ), and tumour necrosis factor (TNF). Even in our more sensitive analysis, these cytokines were not associated with cancer cachexia. Of the 25 circulating factors tested, only monocyte chemoattractant protein-1 (MCP-1) was increased in treatment-naïve cachectic patients compared with weight stable patients and identified as a potential biomarker for cancer cachexia. Although circulating levels of leptin and granulocyte-macrophage colony-stimulating factor (GM-CSF) were found to be decreased in the same cohort of treatment-naïve cachectic patients, these factors were closely associated with body mass index, limiting their utility as cancer cachexia biomarkers. Conclusions: Unlike in advanced disease, it is possible that cachexia in patients with resectable pancreatic cancer is not associated with high levels of classical markers of systemic inflammation. However, cachectic, treatment-naïve patients have higher levels of MCP-1, suggesting that MCP-1 may be useful as a biomarker of cancer cachexia.

AB - Background: Cancer-associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of cancer patients but remains difficult to recognize and diagnose. While increases in circulating levels of a number of inflammatory cytokines have been associated with cancer cachexia, these associations were generally made in patients with advanced disease and thus may be associated with disease progression rather than directly with the cachexia syndrome. Thus, we sought to assess potential biomarkers of cancer-induced cachexia in patients with earlier stages of disease. Methods: A custom multiplex array was used to measure circulating levels of 25 soluble factors from 70 pancreatic cancer patients undergoing attempted tumour resections. A high-sensitivity multiplex was used for increased sensitivity for nine cytokines. Results: Resectable pancreatic cancer patients with cachexia had low levels of canonical pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-1β (IL-1β), interferon-γ (IFN-γ), and tumour necrosis factor (TNF). Even in our more sensitive analysis, these cytokines were not associated with cancer cachexia. Of the 25 circulating factors tested, only monocyte chemoattractant protein-1 (MCP-1) was increased in treatment-naïve cachectic patients compared with weight stable patients and identified as a potential biomarker for cancer cachexia. Although circulating levels of leptin and granulocyte-macrophage colony-stimulating factor (GM-CSF) were found to be decreased in the same cohort of treatment-naïve cachectic patients, these factors were closely associated with body mass index, limiting their utility as cancer cachexia biomarkers. Conclusions: Unlike in advanced disease, it is possible that cachexia in patients with resectable pancreatic cancer is not associated with high levels of classical markers of systemic inflammation. However, cachectic, treatment-naïve patients have higher levels of MCP-1, suggesting that MCP-1 may be useful as a biomarker of cancer cachexia.

KW - Biomarker

KW - Wasting

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=85044737625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044737625&partnerID=8YFLogxK

U2 - 10.1002/jcsm.12251

DO - 10.1002/jcsm.12251

M3 - Article

C2 - 29316343

AN - SCOPUS:85044737625

VL - 9

SP - 358

EP - 368

JO - Journal of Cachexia, Sarcopenia and Muscle

JF - Journal of Cachexia, Sarcopenia and Muscle

SN - 2190-5991

IS - 2

ER -